New Partnership for diagnostic MRI targeting stroke

Ischemic stroke is the target of a new partnership between Oxygen Biotherapeutics (NASDAQ:OXBT) and Aurum Biosciences that aims to develop a diagnostic and a treatment for the condition.

The agreement will pair the companies’ respective technologies: Aurum’s magnetic resonance imaging (MRI) technology has the potential to map salvageable tissue in the brain after a stroke and Oxygen’s technology is being studied as a way to enhance oxygen delivery to the brain. The agreement expands a research pact reached last summer when the companies decided to work together on preclinical stroke research.

Read more